Does radioligand therapy belong earlier in the prostate cancer treatment pathway?

What does 'earlier' actually mean in prostate cancer treatment?

Prostate cancer treatment typically moves through stages: from localized disease to hormone-sensitive metastatic disease (where the cancer still responds to hormone therapy), then to castration-resistant metastatic disease (mCRPC) where it no longer responds to hormone therapy, and finally to heavily pre-treated disease after chemotherapy. Radioligand therapy (RLT) is currently approved for late-stage mCRPC after patients have already tried hormone therapy and chemotherapy [5]. 'Earlier' means moving RLT into the hormone-sensitive phase, or even before chemotherapy, or in patients with less extensive disease like lymph-node-only metastases [1][9].

What evidence shows that earlier use might work better?

The strongest direct evidence comes from a 2021 study of 17 men with lymph-node-only metastases who received RLT. Among these, 58.8% had a PSA decline of at least 50%, and 35.3% dropped to undetectable levels (<0.2 ng/mL). Importantly, men who had not yet received chemotherapy had significantly better PSA responses (p=0.05) [1]. This suggests that earlier treatment, before the cancer becomes more resistant, may be more effective.

Another study from 2022 looked at adding a more powerful alpha-emitting radioligand (actinium-225) to the standard lutetium-177 therapy. Patients who received this 'augmented' therapy early (within the first two cycles) had significantly better progression-free survival (median not reached during the study) compared to those who received it later (median 9 months, p=0.02), and also had less dry mouth (a common side effect) [3]. This supports the idea that earlier intervention, even with a different type of RLT, improves outcomes.

A 2023 study on intermittent RLT in patients with oligometastatic (few metastases) castration-resistant disease found that stopping treatment after an early response and resuming upon progression was feasible, with a median progression-free survival of 27 months and overall survival of 45 months, and no severe toxicity [6]. While this is not a direct comparison to later use, it shows that RLT can be used effectively in less advanced disease states.

Are there trials testing RLT earlier in the pathway?

Yes, the field is actively moving in this direction. A 2025 review identified 25 studies and ongoing clinical trials evaluating RLT in hormone-sensitive prostate cancer, including neoadjuvant (before surgery), adjuvant (after surgery), and early biochemical recurrence settings [9]. These trials are based on the rationale that earlier disease has lower tumor burden, more frequent nodal-only involvement, and higher organ reserve, which may improve efficacy and reduce toxicity [9].

A 2026 clinical consultation guide also notes that evidence is expanding for earlier use in taxane-naïve disease (before chemotherapy) and in metastatic hormone-sensitive prostate cancer [8]. The PSMAfore trial, mentioned in the same guide, is testing RLT in patients who have not yet had chemotherapy, which is a key step toward moving RLT earlier [8][10].

What are the cautions and considerations?

While the evidence is promising, it is not yet definitive. The largest trial, VISION, which led to FDA approval, was in heavily pre-treated patients (after both hormone therapy and chemotherapy) and showed a median overall survival benefit of 15.3 vs 11.3 months [4][5]. This is the current standard, but it does not directly answer the 'earlier' question.

A 2021 study in early-onset prostate cancer (patients ≤55 years) who were chemo-refractory found that RLT yielded similar response rates but shorter survival (median overall survival 8.5 months) compared to other reports, suggesting that even within late-stage disease, earlier treatment (before chemo-refractoriness) may be better [7].

Safety is a key consideration. A 2024 study found that RLT is feasible even in patients with pre-existing moderate to severe thrombocytopenia (low platelets), with no significant worsening of platelet counts and no critical bleeding events [2]. This suggests that RLT can be used safely in some patients who might otherwise be excluded, but it does not address the timing question directly.

Finally, a 2026 review highlights that while RLT is effective, challenges remain in long-term hematologic and renal safety, radionuclide supply, and protocol standardization [10]. These factors will influence how and when RLT is integrated earlier in the pathway.

About These Sources

This answer is built on 10 peer-reviewed studies — published from 2021 to 2026, 4 from 2024 or later, 5 in Q1 journals — selected as the most relevant from 12 studies that passed quality screening, drawn from 60 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions